Crinetics Pharmaceuticals Files 8-K
Ticker: CRNX · Form: 8-K · Filed: Jan 10, 2025 · CIK: 1658247
| Field | Detail |
|---|---|
| Company | Crinetics Pharmaceuticals, Inc. (CRNX) |
| Form Type | 8-K |
| Filed Date | Jan 10, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-statements, exhibits, regulatory-filing
Related Tickers: CRNX
TL;DR
CRNX filed an 8-K with financial statements and exhibits.
AI Summary
On January 10, 2025, Crinetics Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, and other events, with no specific material events or financial figures detailed in the provided text.
Why It Matters
This 8-K filing indicates that Crinetics Pharmaceuticals, Inc. is providing updated financial statements and exhibits, which is a standard regulatory requirement for public companies.
Risk Assessment
Risk Level: low — The filing appears to be routine and does not disclose any new material events, risks, or significant financial changes.
Key Players & Entities
- Crinetics Pharmaceuticals, Inc. (company) — Registrant
- January 10, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 26-3744114 (tax_id) — IRS Employer Identification No.
- 6055 Lusk Boulevard (address) — Principal Executive Offices
- San Diego (location) — City of Principal Executive Offices
- California (state) — State of Principal Executive Offices
- 92121 (zip_code) — ZIP Code of Principal Executive Offices
- (858) 450-6464 (phone_number) — Registrant's Telephone Number
FAQ
What is the primary purpose of this 8-K filing by Crinetics Pharmaceuticals, Inc.?
The filing is a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting on January 10, 2025, and includes information on Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported is dated January 10, 2025.
In which state is Crinetics Pharmaceuticals, Inc. incorporated?
Crinetics Pharmaceuticals, Inc. is incorporated in Delaware.
What is the address of Crinetics Pharmaceuticals, Inc.'s principal executive offices?
The address is 6055 Lusk Boulevard, San Diego, California, 92121.
What is the telephone number for Crinetics Pharmaceuticals, Inc.?
The telephone number, including area code, is (858) 450-6464.
Filing Stats: 908 words · 4 min read · ~3 pages · Grade level 11.6 · Accepted 2025-01-10 07:34:34
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share CRNX Nasdaq Global Select
Filing Documents
- crnx-20250110.htm (8-K) — 46KB
- crnx-ex99_1.htm (EX-99.1) — 42KB
- crnx-ex99_2.htm (EX-99.2) — 23KB
- crnx-ex99_2s1.jpg (GRAPHIC) — 184KB
- crnx-ex99_2s2.jpg (GRAPHIC) — 637KB
- crnx-ex99_2s3.jpg (GRAPHIC) — 401KB
- crnx-ex99_2s4.jpg (GRAPHIC) — 380KB
- crnx-ex99_2s5.jpg (GRAPHIC) — 365KB
- crnx-ex99_2s6.jpg (GRAPHIC) — 336KB
- crnx-ex99_2s7.jpg (GRAPHIC) — 370KB
- crnx-ex99_2s8.jpg (GRAPHIC) — 329KB
- crnx-ex99_2s9.jpg (GRAPHIC) — 324KB
- crnx-ex99_2s10.jpg (GRAPHIC) — 328KB
- crnx-ex99_2s11.jpg (GRAPHIC) — 344KB
- crnx-ex99_2s12.jpg (GRAPHIC) — 251KB
- crnx-ex99_2s13.jpg (GRAPHIC) — 337KB
- crnx-ex99_2s14.jpg (GRAPHIC) — 314KB
- crnx-ex99_2s15.jpg (GRAPHIC) — 440KB
- crnx-ex99_2s16.jpg (GRAPHIC) — 357KB
- crnx-ex99_2s17.jpg (GRAPHIC) — 316KB
- crnx-ex99_2s18.jpg (GRAPHIC) — 253KB
- crnx-ex99_2s19.jpg (GRAPHIC) — 170KB
- crnx-ex99_2s20.jpg (GRAPHIC) — 251KB
- 0000950170-25-003801.txt ( ) — 9447KB
- crnx-20250110.xsd (EX-101.SCH) — 23KB
- crnx-20250110_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements This Current R eport on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act, and Section 21E of the Exchange Act. All statements other than statements of historical facts contained in this Current Report on Form 8-K are forward-looking statements. These forward-looking statements speak only as of the date of this Current Report on Form 8-K and are subject to a number of known and unknown risks, uncertainties and assumptions, including, without limitation, the risks and uncertainties described in the Company's periodic filings with the Securities and Exchange Commission ("SEC"). The events and circumstances reflected in the Company's forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Additional information on risks facing Crinetics can be found under the heading "Risk Factors" in Crinetics' periodic filings with the SEC, including its annual report on Form 10-K for the year ended December 31, 2023 and quarterly reports on Form 10-Q for the quarters ended March 31, 2024, June 30, 2024, and September 30, 2024. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by applicable law, Crinetics does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated January 10, 2025 99.2 Corporate Presentation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Crinetics Pharmaceuticals, Inc. Date: January 10, 2025 By: /s/ R. Scott Struthers, Ph.D. R. Scott Struthers, Ph.D. President and Chief Executive Officer (Principal Executive Officer)